Skip to main content
OpenTrials
Completed

NCT Number: NCT05389696

Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects

1. Part 1 Randimization, Double blinded, Placebo controlled, Dose escalation(10mg, 20mg, 40mg) of MIT-001 SC or IV single administration to evaluate safety, tolerability and PK in healthy adult. 2. Part2 Randimization, Double blinded, Placebo controlled, MIT-001 SC multiple administration for 7days (20mg & 40mg) to evaluate safety, tolerability and PK in healthy adult.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heathly Subjects

Age range

19 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Seoul National University

Seoul, 03080, South Korea

About this study

This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple dose, dose escalation clinical trial in 40 healthy subjects. This study consists of part 1(single dose for group 1, 2, 3) and part 2(multiple dose for 7 days to group 1 and 2). Subjects will be assigned in 6:2 allocation to receive active or placebo treatments. The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic properties of MIT-001 after single and multiple subcutaneous administration in healthy adults and to compare IV administration.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A healthy adult between 19 and 45 at the time of screening
  • A person who weigh 55.0 kg or more and 90.0 kg or less at the time of screening and have a body mass index (BMI) of 18.0 or more and 27.0 or less

☞ BMI (kg/m2) = Weight (kg) / {Height (m)}2

  • A person who voluntarily decides to participate after hearing and fully understanding the detailed explanation of this clinical trial and consents in writing before the screening procedure
  • A person suitable as a test subject for this study when judged by the investigator through physical examination, clinical laboratory examination, questionnaire, etc.

Exclusion criteria

  • Clinically significant liver, kidney, nervous system, immune system, respiratory system, endocrine system disease, blood/tumor disease, cardiovascular disease, mental disease (mood disorder, obsessive-compulsive disorder, etc.) or a history of above diseases
  • A person with a history of hypersensitivity or clinically significant hypersensitivity to clinical investigational drugs, drugs containing the same class of ingredients, and other drugs (aspirin, antibiotics, etc.)
  • At screening, QTc > 450 ms on ECG or other clinically significant findings
  • A person with AST and ALT exceeding 1.5 times the upper limit of the normal range during screening
  • A person with eGFR of less than 60 mL/min/1.73m2 measured using the CKD EPI formula in clinical laboratory tests at screening
  • At screening, systolic blood pressure > 160 mmHg or < 90 mmHg, or diastolic blood pressure > 100 mmHg or < 50 mmHg
  • A person with a history of drug abuse or who have tested positive for drugs of abuse in urine drug screening tests
  • A person who has taken any prescription drugs or herbal medicines within 2 weeks before the first scheduled administration date, or have taken any over-the-counter (OTC), health functional food, or vitamin preparations within 1 week In cases where it is reasonable, they can participate in the clinical trial) or those who are expected to take it
  • A person who has taken drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first scheduled administration date
  • A person who has participated in other clinical trials or bioequivalence studies within 6 months prior to the scheduled first administration date and received the investigational drug or bioequivalence study drug
  • A person who has donated whole blood within 2 months before the first scheduled dose or donated component blood within 1 month, or received blood transfusion within 1 month before the first scheduled dose
  • A person who continuously drinks alcohol (more than 21 units/week, 1 unit = 10 g of pure alcohol (≒ 1 glass of soju or 250 mL of beer)) or cannot abstain from alcohol during the clinical trial period
  • Smokers (However, if you quit smoking 3 months before the first scheduled dose, you can be selected as a test subject)
  • A person who has consumed caffeine-containing foods (coffee, tea (black tea, green tea, etc.), carbonated drinks, coffee milk, nourishing drinks, etc.) within 24 hours of hospitalization for clinical trials and those who cannot refrain from consuming them during hospitalization
  • A person who does not use the following medically acceptable contraceptive methods for 1 month from participation in the clinical trial to the last administration of the investigational drug A. Use of an intrauterine device (copper loop, hormone-containing intrauterine system) with a proven rate of pregnancy failure in the spouse (or partner) B. Concomitant use of either a spermicide or a parenteral hormonal contraceptive with a barrier contraceptive method (male or female) C. Surgery of you or your partner (vasectomy, fallopectomy/ligation, hysterectomy, etc.) D. Use of a cervical cap or contraceptive diaphragm with a male condom
  • Pregnant or lactating women
  • A person who judged the investigator to be inappropriate to participate in the clinical trial due to other reasons

Treatment and study plan

Single subcutaneous administration and Blood collection

Drug

Single subcutaneous administration and Blood collection

Other names: MIT-001 10mg and 20mg

Single subcutaneous administration and then IV injection.

Drug

Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.

Other names: MIT-001 40mg

MIT-001 20mg and 40mg_Multiple administration

Drug

Multiple subcutaneous administration for 7 days and then blood collection

Other names: MIT-001 20mg and 40mg

Primary outcomes

  1. PK_Cmax_Part1 Group 1&2

    Time frame: Part1. Group 1&2: Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part 1, Group 1,2: Cmax

  2. PK_Cmax_Part1 Group 3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: Cmax

  3. PK_AUClast_Part1 Group 1&2

    Time frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part1, Group 1&2: AUClast

  4. PK_AUClast_Part1 Group 3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: AUClast

  5. PK_AUCinf_Part 1, Group 1&2

    Time frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part 1, Group 1&2: AUCinf

  6. PK_AUCinf_Part 1, Group 3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: AUCinf

  7. PK_Tmax_Part 1, Group 1&2

    Time frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part 1, Group 1&2: Tmax

  8. PK_Tmax_Part 1, Group 3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: Tmax

  9. PK_t1/2_Part 1, Group 1&2

    Time frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part 1, Group 1&2: t1/2

  10. PK_t1/2_Part 1, Group 3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: t1/2

  11. PK_Vd/F_Part 1, Group 1&2

    Time frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part 1, Group 1&2: Vd/F

  12. PK_Vd/F_Part 1, Group 3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: Vd/F

  13. PK_CL/F_Part 1, Group 1,2

    Time frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part 1, Group 1,2: CL/F

  14. PK_CL/F_Part 1, Group 3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: CL/F

  15. PK_MRT_Part 1, Group 1&2

    Time frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part 1, Group 1,2: MRT

  16. PK_MRT_Part 1, Group 3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: MRT

  17. PK_F_Part1, Group1,2

    Time frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.

    Part 1, Group 1,2: F

  18. PK_F_Part1, Group3

    Time frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.

    Part 1, Group 3: F

  19. PK_Part2_Cmax

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Cmax

  20. PK_Part2_Cmin

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Cmin, Cavg, AUCtau, Tmax, t1/2, Vd/F, CL/F, Cmax,ss, Cmin,ss, Cavg,ss, AUCtau,ss, Tmax,ss, t1/2,ss, Vdss/F, CLss/F, PTF, Rac

  21. PK_Part2_Cavg

    Time frame: Par2_Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Cavg

  22. PK_Part2_AUCtau

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: AUCtau

  23. PK_Part2_Tmax

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Tmax

  24. PK_Part2_t1/2

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: t1/2

  25. PK_Part2_Vd/F

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Vd/F

  26. PK_Part2_CL/F

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: CL/F

  27. PK_Part2_Cmax,ss

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Cmax,ss

  28. PK_Part2_Cmin,ss

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Cmin,ss

  29. PK_Part2_Cavg,ss

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Cavg,ss

  30. PK_Part2_AUCtau,ss

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: AUCtau,ss

  31. PK_Part2_Tmax,ss

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: Tmax,ss

  32. PK_Part2_t1/2,ss

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: _t1/2,ss

  33. PK_Part2_Vdss/F

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: _Vdss/F

  34. PK_Part2_CLss/F

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: _VCLss/F

  35. PK_Part2_PTF

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: _PTF

  36. PK_Part2_Rac

    Time frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points

    Part 2: _Rac

Sponsors and collaborators

Lead sponsor

MitoImmune Therapeutics

Industry

Registry information

Official study title

Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Characteristics of MIT-001 After Subcutaneous and Intravenous Administration in Healthy Subjects

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 25, 2022
Registry last updated
Aug 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.